Based in West Palm Beach, FL, Third Security is a venture capital firm characterized by an expanding global perspective. Reach out to us to learn more.
Investment Type: Venture Capital
Mentions in press and media 10
| Date | Title | Description |
| 18.03.2014 | Heyo Closes $2M Series A Financing | Heyo, a Blacksburg, VA-based provider of a social marketing platform for small businesses, closed a $2m Series A financing. Valleys’ Ventures, LP, of Radford, VA, was the sole investor in the round, joining David Cohen of Techstars and Paul... |
| 19.07.2013 | What’s special about the 3 biotechs in the top 10 for Q2 venture investments? | But let’s look a little more closely at the those three biotechnology companies and what they say about what is drawing investor attention. Two of the three provide valuable services to other life science companies. The third has a heart fa... |
| 08.10.2012 | Biopharma with personalized cell therapy raises $45M in stock sale, forges collaboration deal | Additionally, Fibrocell agreed to a strategic collaboration with biotechnology firm Intrexon which can provide genome engineering, cell processing, and cell system engineering, among other services, to help advance Fibrocell’s personalized ... |
| 31.05.2011 | Synthetic biotech company Intrexon raises $100M | The money will be directed to Intrexon’s UltraVector platform, the company’s technology used to design and construct complex transgenes to achieve certain qualities that would not typically be found in nature. The engineering can result in ... |
| 13.01.2010 | Synchrony Receives 10m in Series C Funding | Synchrony, Inc., a Salem, Virginia-based producer and supplier of clean technology for rotating machinery and power conversion systems, has received $10m in Series C funding from New River Management VI, a venture fund managed by Third Secu... |
| 25.07.2007 | Cell imager and manipulator Cyntellect collects $15.1M | San Diego’s Cyntellect, a laboratory equipment maker focused on tools that image and manipulate living cells, raised $15.1 million in a fourth funding round. The company’s technology, which it says is based upon principles from the semicond... |
| 16.05.2007 | Intrexon picks up $25M for gene therapy | Intrexon, a Blackburg, Va., developer of engineered gene therapies it calls “transcriptional therapeutics,” raised $25 million in a third round of financing provided by Third Security. Earlier funding rounds were provided by Third Security ... |
| - | Biopharma with personalized cell therapy raises $45M in stock sale, forges collaboration deal | A company with the first FDA-approved personalized cell therapy for reducing wrinkles has raised $45 million in a private stock sale. The financing was sought to improve manufacturing capacity for the therapy and advance other uses for it s... |
| - | What’s special about the 3 biotechs in the top 10 for Q2 venture investments? | Cellular engineering, precision medicine, and using G protein-coupled receptors to treat heart failure and other conditions. That’s the focus of the three biotechnology companies that made the top 10 for venture investment deals last quarte... |
| - | Synthetic biotech company Intrexon raises $100M | Synthetic biotechnology company Intrexon — whose website is the descriptive www.dna.com — has raised $100 million that the company will use to expand its genetics technology. With the closing of its series E round of fundraising, Blacksburg... |